PubMed Health⌕ Search

Biomedical subjects

F Tavoni

Publications and source records attributed to F Tavoni.

7 recordsLinked to original sources
PubMed1993

Combination treatment in M1 prostate cancer.

The treatment of advanced prostate cancer is based on hormone manipulation to eliminate the trophic effect of testosterone on sensitive androgen tissue of the tumor. In this study, we evaluated the efficacy of the partial androgen blockage versus the complete androgen blockage. One hundred, twenty-two patients were entered in this study and randomly were treated with buserelin alone or with buserelin and flutamide. The group that received buserelin was given cyproterone acetate (200 mg/day) during first 3 weeks of treatment to avoid "flare-up". During the follow-up (range 0-244 +/- 1 weeks), we evaluated 59 patients (61.4%) that had positive response and 37 patients (38.6%) that showed progressive disease: There were no statistically significant differences between the two treatment groups, not even in the evaluation of median time to response and of median time to treatment failure. In conclusion, the results emphasize that total androgenic blockage is as effective as a luteinizing hormone-releasing hormone analog used alone.

Aged↗
PubMed1992

Chemoimmunotherapy for prophylaxis of recurrence in superficial bladder cancer: interferon-alpha 2b versus interferon-alpha 2b with epirubicin.

Eighty-five patients who had undergone transurethral resection (TUR) of superficial bladder cancer were randomized to one of two treatments. Patients in Group 1 received a 10-month course of intravesical therapy with interferon (IFN)-alpha 2b (50 MU dose), commencing 21 days after TUR once a week for 8 weeks, then once every 15 days for 4 months and then finally once a month for 4 months. Patients in Group 2 received epirubicin (80 mg) intravesically 0, 24 and 48 h after TUR, and then 21 days after TUR received IFN-alpha 2b as for Group 1. The results confirmed the efficacy of immunoprophylaxis with IFN-alpha 2b, and early treatment with epirubicin tended to further reduce the percentage of relapses and extended the disease-free interval.

Antineoplastic Combined Chemotherapy Protocols↗
PubMed1984

[Hematologic changes in renal neoplasms].

The main haematological parameters, particularly haemoglobin concentration and the numbers of leukocytes and platelets, were studied in 146 kidney tumour patients. Only 119 of the subjects studied later underwent nephrectomy. In 66 patients the tumours were limited to within the renal capsule (group I) while in 39 other subjects the tumours had gone beyond this limit and had invaded the perirenal tissue (group II). 27 patients had metastasis in one or more sites (group III). In the remaining 14 subjects (group IV) without proven metastasis, the surgical staging was not available since because of cachexia they were not undergone nephrectomy. More frequent signs were: anaemia (Hb less than 12 g/dl), mainly normochromic, found in a high percentage of cases (41% in group I, 59% in group II, 74% in group III, 79% in group IV); leukocytosis (G.B. greater than 8000/mm3: 38% in group I, 51% in group II, 37% in group III, 50% in group IV). Mild thrombocytosis (P = 350-500 X 10(3)/mm3) was found with notable frequency mainly in groups II and III (20% and 18% respectively). On the other hand leukopenia (G.B. less than 3500 per mm3) and thrombocytopenia (P less than 140 X 10(3) per mm3) were rather rare. The results of our study are also discussed in relation to the main findings in the literature.

Adult↗